Gender effect on neuromyelitis optica spectrum disorder with aquaporin4-immunoglobulin G

Multiple Sclerosis

Volumn 23, Issue 8, 2017, Pages 1104-1111

  Kim, Sung Min ^a   Waters, Patrick ^b   Woodhall, Mark ^b   Kim, Yoo Jin ^a   Kim, Jin Ah ^a   Cheon, So Young ^a   Lee, Sehoon ^c   Jo, Seong Rae ^c   Kim, Dong Gun ^c   Jung, Kyeong Cheon ^a   Lee, Kwang Woo ^a   Sung, Jung Joon ^a   Park, Kyung Seok ^a,c  

^a Seoul National University   (South Korea)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c Seoul National University Bundang Hospital   (South Korea)

Author keywords

age; anti aquaporin4 antibody; gender; multiple sclerosis; Neuromyelitis optica; sex

Indexed keywords

AQUAPORIN 4; IMMUNOGLOBULIN G; AQP4 PROTEIN, HUMAN; AUTOANTIBODY;

ARTICLE; DISEASE SEVERITY; EVOKED RESPONSE; FEMALE; HUMAN; LATENT PERIOD; MAJOR CLINICAL STUDY; MALE; MYELOOPTIC NEUROPATHY; ONSET AGE; OUTCOME ASSESSMENT; PROGNOSIS; SEX DIFFERENCE; VISUAL EVOKED POTENTIAL; ADULT; CONTROLLED STUDY; FOLLOW UP; MYELITIS; OPTIC NEURITIS; AGE; IMMUNOLOGY; MIDDLE AGED; SEXUAL CHARACTERISTICS; YOUNG ADULT;

ADULT; AGE FACTORS; AGE OF ONSET; AQUAPORIN 4; AUTOANTIBODIES; EVOKED POTENTIALS, VISUAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; NEUROMYELITIS OPTICA; SEX CHARACTERISTICS; YOUNG ADULT;

EID: 85046089234     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458516674366     Document Type: Article

References (27)

1. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85: 177-189.
2. Wingerchuk DM,. Neuromyelitis optica: Effect of gender. J Neurol Sci 2009; 286: 18-23.
3. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 805-815.
4. Marignier R, Bernard-Valnet R, Giraudon P, et al. Aquaporin-4 antibody-negative neuromyelitis optica: Distinct assay sensitivity-dependent entity. Neurology 2013; 80: 2194-2200.
5. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302.
6. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485-1489.
7. Young N, Weinshenker B, Lucchinetti C,. Acute disseminated encephalomyelitis: Current understanding and controversies. Semin Neurol 2008; 28: 84-94.
8. Román G,. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology 2003; 60: 730-731.
9. Shams P, Plant G,. Optic neuritis: A review. Int MS J 2009; 16: 82-89.
10. Tintore M, Rovira A, Arrambide G, et al. Brainstem lesions in clinically isolated syndromes. Neurology 2010; 75: 1933-1938.
11. Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: A multicenter comparison of aquaporin-4-IgG assays. Neurology 2012; 78: 665-671; discussion 669.
12. Waters P, Jarius S, Littleton E, et al. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol 2008; 65: 913-919.
13. Kurtzke JF,. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
14. Kim SM, Waters P, Vincent A, et al. Cerebrospinal fluid/serum gradient of IgG is associated with disability at acute attacks of neuromyelitis optica. J Neurol 2011; 258: 2176-2180.
15. Odom J, Bach M, Brigell M, et al. ISCEV standard for clinical visual evoked potentials (2009 update). Doc Ophthalmol 2010; 120: 111-119.
16. Klem G, Lüders H, Jasper H, et al. The ten-twenty electrode system of the International Federation. The International Federation of Clinical Neurophysiology. Electroencephalogr Clin Neurophysiol Supp 1999; 52: 3-6.
17. Emmerson-Hanover R, Shearer D, Creel D, et al. Pattern reversal evoked potentials: Gender differences and age-related changes in amplitude and latency. Electroencephalogr Clin Neurophysiol 1994; 92: 93-101.
18. Kitley J, Leite M, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 2012; 135: 1834-1849.
19. Wingerchuk DM, Weinshenker B,. Neuromyelitis optica: Clinical predictors of a relapsing course and survival. Neurology 2003; 60: 848-853.
20. Sato D, Callegaro D, Lana-Peixoto M, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014; 82: 474-481.
21. Morales LB, Loo KK, Liu HB, et al. Treatment with an estrogen receptor alpha ligand is neuroprotective in experimental autoimmune encephalomyelitis. J Neurosci 2006; 26: 6823-6833.
22. Spence RD, Wisdom AJ, Cao Y, et al. Estrogen mediates neuroprotection and anti-inflammatory effects during EAE through ERalpha signaling on astrocytes but not through ERbeta signaling on astrocytes or neurons. J Neurosci 2013; 33: 10924-10933.
23. Shughrue P, Lane M, Merchenthaler I,. Comparative distribution of estrogen receptor-alpha and -beta mRNA in the rat central nervous system. J Comp Neurol 1997; 388: 507-525.
24. Ringelstein M, Kleiter I, Ayzenberg I, et al. Visual evoked potentials in neuromyelitis optica and its spectrum disorders. Mult Scler 2014; 20: 617-620.
25. Kim S, Waters P, Woodhall M, et al. Utility of aquaporin-4 antibody assay in patients with neuromyelitis optica spectrum disorders. Mult Scler 2013; 19: 1060-1067.
26. Jeong I, Kim H, Kim N, et al. Subclinical primary retinal pathology in neuromyelitis optica spectrum disorder. J Neurol 2016; 263: 1343-1348.
27. Mao Z, Yin J, Zhong X, et al. Late-onset neuromyelitis optica spectrum disorder in AQP4-seropositivepatients in a Chinese population. BMC Neurol 2015; 15: 160.